Ischemic StrokePhase 3NCT05439356
Colchicine in High-risk Patients With Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3)
A Phase 3 study testing Colchicine in people with Ischemic Stroke and TIA, run by Beijing Tiantan Hospital at 244 sites in China.
Trial summary
This study is a multicentre, randomized, double-blind, placebo-controlled, investigator-sponsored study that aims to investigate the efficacy of colchicine in preventing recurrent stroke in the patients with acute minor-to-moderate ischemic stroke or TIA and a hsCRP level of ≥2mg/L. Read more about this study
- Who is it for?
- Ages 40 years and older
- Conditions the study is for
- Ischemic Stroke, TIA
- What is being tested?
- Colchicine
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 8,343 participants
- Where
- 244 sitesChina
- Study dates
- 11 Aug 2022to 12 Apr 2024
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 40 years or older than 40 years;
- Acute cerebral ischemic event due to: Acute minor-to-moderate ischemic stroke (NIHSS≤5 at the time of randomization) or TIA with moderate-to-high risk of stroke (ABCD2 score ≥ 4 at the time of randomization);
- With a hsCRP level of ≥2mg/L at randomization;
- Can be treated with study drug within 24 hours of symptoms onset*(*Symptom onset is defined by the "last seen normal" principle);
- Informed consent signed.
Who cannot join
- Malformation, tumor, abscess or other major non-ischemic brain disease (e.g., multiple sclerosis) on baseline head CT or MRI.
- Isolated or pure sensory symptoms (e.g., numbness), isolated visual changes, or isolated dizziness/vertigo without evidence of acute infarction on baseline head CT or MRI.
- Iatrogenic causes (angioplasty or surgery) of stroke or TIA.
- Presumed cardiac source of embolus, such as atrial fibrillation or prosthetic cardiac valve).
- A score of ≥ 2 on the modified Rankin scale immediately before the occurrence of the index event.
- Usage of colchicine within 30 days before randomization or planning to take colchicine therapy for other indications.
Show all 21Show fewer
- Known allergy or sensitivity or intolerance to colchicine.
- Inflammatory bowel disease (Crohn's or ulcerative colitis) or chronic diarrhea.
- Symptomatic peripheral neuropathy or pre-existing progressive neuromuscular disease or with creatine kinase (CK) level > 3 times the upper limit of normal as measured within the past 30 days and determined to be non-transient through repeat testing.
- A history of cirrhosis, chronic active hepatitis or severe hepatic disease.
- Impaired hepatic (ALT or AST > twice the upper limit of normal range) or kidney (creatinine exceeding 1.5 times of the upper limit of normal range or eGFR less than 50 ml/min) function at randomization.
- Anemia (haemoglobin <10g/dL), thrombocytopenia (platelet count <100×109/L) or leucopenia (white blood cell <3×109/L) at randomization.
- In the acute phase of respiratory tract infection, urinary tract infection, and gastro-enteritis, or currently using or planning to receive oral or intravenous anti-infective therapy for any other infection.
- Currently using or planning to begin long-term (>7 days) systemic anti-inflammatory drugs (NSAIDs except for aspirin, oral or intravenous steroid therapy) during the study.
- Planning to use moderate or strong CYP3A4 inhibitors (clarithromycin, erythromycin, telithromycin, other macrolide antibiotics, ketoconazole, itraconazole, voriconazole, ritonavir, atazanavir, indinavir, other HIV protease inhibitors, verapamil, diltiazem, quinidine, digoxin, disulfiram, etc) or P-gp inhibitors (cyclosporine) at randomization.
- Planned surgery or interventional treatment requiring cessation of the study drug during the study.
- Participating in another clinical trial with an investigational drug or device concurrently or during the last 30 days.
- Women of childbearing age who were not practicing reliable contraception and did not have a documented negative pregnancy test or severe noncardiovascular coexisting condition.
- Severe non-cardiovascular comorbidity with a life expectancy of less than 3 months.
- With a history of clinically significant drug or alcohol abuse.
- Inability to understand and/or follow research procedures due to mental, cognitive, or emotional disorders, or to be an unsuitable candidate for the study for any other considered by the investigator.
Trial locations and contacts
244 sites in 1 country.
244 sites in 1 country
China244 sites
Ankang Central Hospital
Ankang, Shaanxi
Anshan Central Hospital
Anshan, Liaoning
Puding County People's Hospital
Anshun, Guizhou
The People's Hospital of Anyang City
Anyang, Henan
Baise City People's Hospital
Baise City, Guangxi
Affiliated Hospital of Hebei University
Baoding, Hebei
Baoding Xushui District People's Hospital
Baoding, Hebei
Hebei Tang County People Hospital
Baoding, Hebei
Shunping County Hospital
Baoding, Hebei
The Hospital of Anguo City
Baoding, Hebei
Wangdu County Hospital,Hebei Province
Baoding, Hebei
Baotou City Central Hospital
Baotou, Inner Mongolia
Sinopharm North Hospital
Baotou, Inner Mongolia
The First Affiliated Hospital of Baotou Medical College
Baotou, Inner Mongolia
The people's Hospital of Wulateqianqi
Bayan Nur, Inner Mongolia
Wuyuan County People's Hospital
Bayan Nur, Inner Mongolia
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, 100070
Beijing Shunyi Airport Hospital
Beijing, Beijing Municipality
Beijing Shunyi Hospital
Beijing, Beijing Municipality
Fuxing Hospital, Capital Medical University
Beijing, Beijing Municipality
The First Hospital of Fangshan District, Beijing
Beijing, Beijing Municipality
Zhejiang Provincial People's Hospital Bijie Hospital
Bijie, Guizhou
Binzhou Central Hospital
Binzhou, Shandong
Yangxin County People Hospital
Binzhou, Shandong
China-Japan Union Hospital of Jilin University
Changchun, Jilin
Affiliated Hospital of Chengde Medical University
Chengde, Hebei
Chengde County Hospital
Chengde, Hebei
Sichuan Provincial People's Hospital
Chengdu, Sichuan
The First People's Hospital of Longquanyi Disdrict,Chengdu
Chengdu, Sichuan
Chenzhou No.1 People's Hospital
Chenzhou, Hunan
The Fourth People's Hospital of Chenzhou
Chenzhou, Hunan
The Third People's Hospital of Chenzhou
Chenzhou, Hunan
Chongqing Sanbo Chang 'an Hospital
Chongqing, Chongqing Municipality
Chongqing Tungwah Hospital
Chongqing, Chongqing Municipality
Chongqing University Fuling Hospital
Chongqing, Chongqing Municipality
The First Affiliated Hospital of Chongqing Medical and Pharmaceutical College
Chongqing, Chongqing Municipality
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality
Xiushan Tujia and Miao Autonomous County People's Hospital
Chongqing, Chongqing Municipality
Affiliated Zhongshan Hospital of Dalian University
Dalian, Liaoning
Central Hospital of Wafangdian
Dalian, Liaoning
Central Hospital of Zhuanghe City
Dalian, Liaoning
Dalian Jinzhou District First People's Hospital
Dalian, Liaoning
Dalian Lvshun District Hospitai of tradition Chinese Medicine
Dalian, Liaoning
Dalian Lvshun District People's Hospital
Dalian, Liaoning
Dalian Municipal Central Hospital
Dalian, Liaoning
Dalian PuLanDian central hospital
Dalian, Liaoning
Dalian University Affiliated Xinhua Hospital
Dalian, Liaoning
People's Hospital of Deyang City
Deyang, Sichuan
Dengzhou Central Hospital
Dezhou, Henan
Ningjin People's Hospital
Dezhou, Shandong
People's Hospital of Qihe County
Dezhou, Shandong
The Second People's Hospital of Dongying
Dongying, Shandong
The First People's Hospital of Foshan
Foshan, Guangdong
Linquan County People's Hospital
Fuyang, Anhui
Fuzhou First People's Hospital of Jiangxi Province
Fuzhou, Jiangxi
Nanfang Hospital,Ganzhou
Ganzhou, Jiangxi
Guangdong second Provincial Central Hospital
Guangzhou, Guangdong
The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong
The First People's Hospital of Guiyang
Guiyang, Guizhou
The Second People's Hospital of Guiyang
Guiyang, Guizhou
The Third People's Hospital of Guiyang
Guiyang, Guizhou
Guihang Guiyang hospital
Guizhou, Guiyang
Guyuan people's hospital
Guyuan, Ningxia
The Second Affiliated Hospital of Hainan Medical University
Haikou, Hainan
Guantao county central Hospital
Handan, Hebei
Handan First Hospital
Handan, Hebei
Qiu County Hospital of Traditional Chinese Medicine
Handan, Hebei
Qiu County People's Hospital
Handan, Hebei
The First People's Hospital of jiande
Hangzhou, Zhejiang
The 2nd Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang
The First Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang
Hebi Coal Industry (Group) Co., Ltd. General Hospital
Hebi, Henan
Hejian People's Hospital
Hejian, Hebei
Hengshui People's Hospital
Hengshui, Hebei
The No.4 People's Hospital of Hengshui(Department of Neurology ward 1)
Hengshui, Hebei
The No.4 People's Hospital of Hengshui(Department of Neurology ward 2)
Hengshui, Hebei
Hengyang Central Hospital
Hengyang, Hunan
The Fifth Affiliated Hospital of Jinan University (Heyuan Shenhe People's Hospital)
Heyuan, Guangdong
Yuncheng County People's Hospital
Heze, Shandong
Juancheng County People's Hospital
Heze
Huhhot First Hospital
Hohhot, Inner Mongolia
Inner Mongolia International Mongolian Hospital
Hohhot, Inner Mongolia
Inner Mongolia People's Hospital
Hohhot, Inner Mongolia
Tuoketuo County Hospital
Hohhot, Inner Mongoria
Huangshan City People's Hospital
Huangshan City, Anhui
Huizhou First Hospital
Huizhou, Guangdong
The Second People's Hospital of Huludao
Huludao, Liaoning
Inner Mongolia Forestry General Hospital
Hulunbuir, Inner Mongolia
People's Hospital of Anji
Huzhou, Zhejiang
Boai People's Hospital
Jiaozuo, Henan
Mengzhou Hospital of Traditional Chinese Medicine
Jiaozuo, Henan
Mengzhou People's Hospital(Department of Neurology ward 1)
Jiaozuo, Henan
Mengzhou People's Hospital(Department of Neurology ward 2)
Jiaozuo, Henan
Qinyang City Hospital of Traditional Chinese Medicine
Jiaozuo, Henan
Qinyang People's Hospital
Jiaozuo, Henan
Wuzhi County People's Hospital
Jiaozuo, Henan
Xiuwu County People's Hospital
Jiaozuo, Henan
Haiyan People's Hospital
Jiaxing, Zhejiang
Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Jinan, Shandong
Jingdezhen No.1 People's Hospital
Jingdezhen, Jiangxi
Jiujiang No.1 People's Hospital
Jiujiang, Jiangxi
Jiujiang University Affiliated Hospital
Jiujiang, Jiangxi
Jiyuan Hospital of Traditional Chinese Medicine
Jiyuan, Henan
Kaifeng Central Hospital
Kaifeng, Henan
Lankao County Central Hospital
Kaifeng, Henan
Weishi Central Hospital
Kaifeng, Henan
The People's Hospital of the Qiandongnan Miao and Dong Autonomous Prefecture
Kaili, Guizhou
The second Affiliated Hospital of Guizhou Medical University
Kaili, Guizhou
First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan
The First People's Hospital of Lanzhou City
Lanzhou, Gansu
Guanxian People's Hospital
Liaocheng, Shandong
Liaocheng City Central Hospital
Liaocheng, Shandong
Liaocheng People's Hospital(Liaocheng Brain Hospital)
Liaocheng, Shandong
Liaocheng People's Hospital
Liaocheng, Shandong
The People's Hospital of Gaotang
Liaocheng, Shandong
The people's Hospital of Linqing
Liaocheng, Shandong
The Second People's Hospital of Liaocheng
Liaocheng, Shandong
Third People's Hospital of Liaocheng
Liaocheng, Shandong
Yanggu Traditional Chinese Medical Hospital
Liaocheng, Shandong
Linfen Central Hospital (neurology department)
Linfen, Shanxi
Linfen Central Hospital(emergency department)
Linfen, Shanxi
Linyi Central Hospital
Linyi, Shandong
Linyi People's Hospital
Linyi, Shandong
Linyi Third People's Hospital
Linyi, Shandong
Linyi Traditional Chinese Medicine Hospital
Linyi, Shandong
People's Hospital of Yinan
Linyi, Shandong
Luoning County People's Hospital
Luoyang, Henan
Luoyang Central Hospital
Luoyang, Henan
Luoyang Dongfang People's Hospital
Luoyang, Henan
Luoyang First People's Hospital
Luoyang, Henan
Luoyang Mengjin District People's Hospital
Luoyang, Henan
Ruyang People's Hospital
Luoyang, Henan
The Second Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan
Yiyang County People's Hospital
Luoyang, Henan
Meihekou Central Hospital
Meihekou, Jilin
The Third Hospital of Mianyang
Mianyang, Sichuan
Jiangxi Provincial People's Hospital
Nanchang, Jiangxi
Nanjing Gaochun People's Hospital
Nanjing, Jiangsu
Jiangsu Rudong County People's Hospital
Nantong, Jiangsu
Nantong Tongzhou District No.8 People's Hospital
Nantong, Jiangsu
Suxitong Science and Technology Industrial Park People's Hospital
Nantong, Jiangsu
The People's Hospital of Rugao
Nantong, Jiangsu
The Sixth People's Hospital of Nantong
Nantong, Jiangsu
Nanyang Second General Hospital
Nanyang, Henan
Neixiang County People's Hospital
Nanyang, Henan
Xichuan County People's Hospital
Nanyang, Henan
Xixia County People's Hospital
Nanyang, Henan
The Second People's Hospital of Neijiang
Neijiang, Sichuan
Ningde People's Hospital
Ningde, Fujian
Yunnan Nujiang Lisu Autonomous Prefecture People's Hospital
Nujiang, Yunnan
Ordos central hospital
Ordos, Inner Mongolia
Panjin Central Hospital
Panjin, Liaoning
Panzhihua Central Hospital
Panzhihua, Sichuan
Ruzhou People's Hospital
Pingdingshan, Henan
The second people's hospital of Pingdingshan
Pingdingshan, Henan
Ye County People's Hospital
Pingdingshan, Henan
Ninger County People's Hospital
Pu'er, Yunnan
Fanxian People's Hospital
Puyang, Henan
Puyang County People's Hospital
Puyang, Henan
Qingfeng xinxing hospital
Puyang, Henan
Qingdao Fuwai Cardiovascular Hospital
Qingdao, Shandong
Qixia City People's Hospital
Qixian, Shandong
The First People Hospital of Lingbao
Sanmenxia, Henan
The Sanming First Hospital Affiliated to Fujian Medical University
Sanming, Fujian
Shanghai Seventh People's Hospital
Shanghai, Shanghai Municipality
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine,Shanghai University of Traditional Chinese Medicine
Shanghai, Shanghai Municipality
Sui county traditional Chinese medicine hospital
Shangqiu, Henan
The Fourth People's Hospital of Shangqiu
Shangqiu, Henan
The Shangqiu First People's Hospital
Shangqiu, Henan
Zhecheng People's Hospital
Shangqiu, Henan
ShangRao People's Hospital
Shangrao, Jiangxi
Yugan Xinjiang hospital
Shangrao, Jiangxi
Shaodong People's Hospital
Shaoyang, Hunan
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Shenyang, Liaoning
Shengjing Hospital of China Medical University
Shenyang, Liaoning
The People's Hospital of Liaoning Province
Shenyang, Liaoning
The First Affiliated Hospital of Shihezi University
Shihezi, Xinjiang
Shijiazhuang Third Hospital
Shijiazhuang, Hebei
The Second Hospital of Hebei Medical University
Shijiazhuang, Hebei
Hongxinglong Hospital of Beidahuang Group
Shuangyashan, Heilongjiang
Siping Central People's Hospital
Siping, Jilin
Nanjing Drum Tower Hospital Group Suqian Hospital
Suqian, Jiangsu
Siyang kangda hospital
Suqian, Jiangsu
Second Hospital of Shanxi Medical University
Taiyuan, Shanxi
Shanxi Bethune Hospital
Taiyuan, Shanxi
Shanxi Cardiovascular Hospital
Taiyuan, Shanxi
Xinghua City People's Hospital
Taizhou, Jiangsu
North China University of Science And Technology Affiliated Hospital
Tangshan, Hebei
Tangshan Gongren Hospital
Tangshan, Hebei
Tengchong People's Hospital
Tengyue, Yunnan
Affiliated Hospital of Inner Mongolia Minzu University
Tongliao, Inner Mongolia
Tongliao City Hospital
Tongliao, Inner Mongolia
Ulanpab Central Hospital
Ulanqab, Inner Mongolia
People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, China
Ürümqi, Xinjiang
Weihai Wendeng District People's Hospital
Weihai, Shandogn
Weihai Central Hospital
Weihai, Shandong
Weihai Municipal Hospital
Weihai, Shandong
The people's Hospital of Wuhai
Wuhai, Inner Mongolia
The First Affiliated Hospital of Wannan Medical College
Wuhu, Anhui
The First People's Hospital of Wuhu
Wuhu, Anhui
Jiangyin People's Hospital
Wuxi, Jiangsu
Yixing People's Hospital
Wuxi, Jiangsu
The People's Hospital of Cenxi City
Wuzhou, Guangxi
East District of The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi
Xi 'an Fengcheng Hospital
Xi'an, Shaanxi
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian
The Second affiliated Hospital of Xiamen Medical College
Xiamen, Fujian
The Third Hospital of Xiamen
Xiamen, Fujian
Xianyang Hospital of Yan 'an University
Xianyang, Shaanxi
Qinghe people's hospital
Xingtai, Hebei
Werixian People's Hospital
Xingtai, Hebei
Qianxinan Buyi and Miao Autonomous Prefecture People's Hospital
Xingyi, Guizhou
Huixian People's Hospital
Xinxiang, Henan
The second People Hospital of Xinxiang Henan
Xinxiang, Henan
Xinxiang tongmeng hospital
Xinxiang, Henan
The Affiliated Hospital of Xinyang Vocational and Technical College
Xinyang, Henan
The Second Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu
Zichang People's Hospital
Yan’an, Shaanxi
Qixia traditional Chinese medicine hospital
Yantai, Shandong
Yantai Affiliated Hospital of Binzhou Medical University
Yantai, Shandong
Yantai Penglai People's Hospital
Yantai, Shandong
Yantai Penglai traditional Chinese medicine hospital
Yantai, Shandong
Yantai Taocun Central Hospital
Yantai, Shandong
Yantai Yuhuangding Hospital
Yantai, Shandong
Yantai Zhifu hospital
Yantai, Shandong
YEDA hospital
Yantai, Shandong
Tonggu County People's Hospital
Yichun, Jiangxi
Yichun People's Hospital
Yichun, Jiangxi
Central Hospital of Yongcheng
Yongcheng, Henan
Yueyang People's Hospital
Yueyang, Hunan
Yicheng Municipal Hospital of Zaozhuang
Zaozhuang, Shandong
The First Affiliated Hospital of Hebei North University
Zhangjiakou, Hebei
Zhangye People's Hospital Affiliated To Hexi University
Zhangye, Gansu
Xingyang People's Hospital
Zhengzhou, Henan
Xinmi Hospital of T.C.M
Zhengzhou, Henan
People's Hospital of Zhongwei
Zhongwei, Ningxia
Shenqiu County People's Hospital
Zhoukou, Henan
Taikang Xian People's Hospital
Zhoukou, Henan
Xihua Xian People's Hospital
Zhoukou, Henan
Zhumadian TCM Hospital
Zhumadian, Henan
PKUcare Zibo Hospital
Zibo, Shandong
Zibo Central Hospital
Zibo, Shandong
Zibo Hospital of Traditional Chinese Medicine
Zibo, Shandong
Zibo Municipal Hospital
Zibo, Shandong
About this study
This study is a multicentre, randomized, double-blind, placebo-controlled, investigator-sponsored study that aims to investigate the efficacy of colchicine in preventing recurrent stroke in the patients with acute minor-to-moderate ischemic stroke or TIA and a hsCRP level of ≥2mg/L.
Read the detailed description
This is a multicentre, randomized, double-blind, placebo-controlled trial that aims to investigate the efficacy of colchicine in preventing recurrent stroke in the patients with acute minor-to-moderate ischemic stroke or TIA and a hsCRP level of ≥2mg/L. Patients who were eligible to the inclusion criteria and ineligible to the exclusion criteria will be randomly assigned into two groups by a 1:1 ratio. Patients in one arm will receive colchicine initiated with a dose of 1mg per day on days 1 through 3, and continuing with 0.5 mg per day on days 4 through 90, and those in the other arm will receive an equivalent placebo drug. Study visits will be performed on the day of randomization, at discharge, at day 90 and at 1 year. The primary outcome was stroke (ischemic or hemorrhagic) during 90 days of follow-up in an intention-to treat analysis.
- Conditions
- Ischemic Stroke, TIA
- Being tested
- Colchicine, Placebo colchicine
- Medical subject headings
- Ischemic Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ColchicineDrug
Oral colchicine will be initiated with a dose of 1mg per day (one tablet of 0.5mg initially followed by another tablet of 0.5 mg at least four hours later) on days 1 through 3, and continuing with 0.5 mg (one tablet) per day on days 4 through 90.
Placebo colchicineDrug
Oral placebo colchicine will be initiated with a dose of 1mg per day (one tablet of 0.5mg initially followed by another tablet of 0.5 mg at least four hours later) on days 1 through 3, and continuing with 0.5 mg (one tablet) per day on days 4 through 90.
| Study group | Role | What they receive |
|---|---|---|
| Colchicine Group | Experimental | Patients in this arm will receive colchicine for 90 days in addition to standard medical care Receives: Drug: Colchicine |
| Placebo Colchicine Group | Placebo comparator | Patients in this arm will receive placebo colchicine for 90 days in addition to standard medical care Receives: Drug: Placebo colchicine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Any new stroke events
Incidence of any new ischemic or hemorrhagic stroke
Measured: any time within 90 days
Secondary outcomes (5)
New vascular events
Incidence of any new vascular events, including ischemic stroke, hemorrhagic stroke, TIA, myocardial infarction and vascular death
Measured: any time within 90 days
New ischemic stroke
Incidence of any new ischemic stroke
Measured: any time within 90 days
Poor functional outcome
Rate of poor functional outcome defined as a Modified Rankin Scale score of >1 (Modified Rankin Scale score ranges from 0 (no symptoms) to 6 (death) and higher score means worse outcome)
Measured: at 90 days after randomization
New stroke and TIA
Incidence of any new stroke and TIA
Measured: any time within 90 days
Severity of recurrent stroke and TIA
Severity is measured using a six-level ordered categorical scale that incorporates the mRS: fatal stroke [mRS 6]/severe non-fatal stroke [mRS 4 or 5]/moderate stroke [mRS 2 or 3]/mild stroke [mRS 0 or 1]/TIA/no stroke-TIA
Measured: within 90 days after randomization
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jun 2022
- Study start11 Aug 2022
- Primary completion13 Jul 2023
- Study completion12 Apr 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Ischemic StrokeStudies of the same condition, open and under way.
- More trials run by Beijing Tiantan HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 8,343 participants (actual)
Sponsor and investigators
- Lead sponsor
- Beijing Tiantan Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yongjun Wang, Beijing Tiantan Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05439356
- Sponsor's protocol ID
- NCRC-2022-05
- Status last verified
- Jun 2024
- First submitted
- 20 Jun 2022
- Last updated
- 25 Jun 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Data collected for the study can be made available to other researchers on reasonable request and after signing appropriate data sharing agreements.
Publications
Li J, Jing J, Meng X, Shi FD, Gu HQ, Jin A, Jiang Y, Li H, Johnston SC, Hankey GJ, Easton JD, Xie X, Jin WN, Chang L, Shi P, Wang L, Zhuang X, Li H, Zang Y, Zhang J, Sun Z, Liu D, Li Y, Yang H, Zhao J, Yu W, Wang A, Pan Y, Lin J, Li S, Niu S, Wang Y, Zhao X, Li Z, Liu L, Zheng H, Wang Y; CHANCE-3 Investigators. Colchicine for preventing stroke in patients with and without intracranial atherosclerotic stenosis: a prespecified analysis of a randomized clinical trial. EClinicalMedicine. 2025 May 19;84:103226. doi: 10.1016/j.eclinm.2025.103226. eCollection 2025 Jun.
PubMed 40496882Li J, Meng X, Shi FD, Jing J, Gu HQ, Jin A, Jiang Y, Li H, Johnston SC, Hankey GJ, Easton JD, Chang L, Shi P, Wang L, Zhuang X, Li H, Zang Y, Zhang J, Sun Z, Liu D, Li Y, Yang H, Zhao J, Yu W, Wang A, Pan Y, Lin J, Xie X, Jin WN, Li S, Niu S, Wang Y, Zhao X, Li Z, Liu L, Zheng H, Wang Y; CHANCE-3 Investigators. Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): multicentre, double blind, randomised, placebo controlled trial. BMJ. 2024 Jun 26;385:e079061. doi: 10.1136/bmj-2023-079061.
PubMed 38925803Wang Y, Li J, Johnston SC, Hankey GJ, Easton JD, Meng X, Shi FD, Wang Y, Zhao X, Li Z, Liu L, Gu H, Jiang Y, Wang A, Pan Y, Jing J, Niu S, Li H. Colchicine in High-risk Patients with Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3): Rationale and design of a multicenter randomized placebo-controlled trial. Int J Stroke. 2023 Aug;18(7):873-878. doi: 10.1177/17474930231172312. Epub 2023 May 11.
PubMed 37060288
Study at a glance
From the registry record, last updated by the sponsor on 25 Jun 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Colchicine in High-risk Patients With Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3)
- ClinicalTrials.gov ID
- NCT05439356
- Acronym / sponsor ID
- NCRC-2022-05
- Conditions
- Ischemic Stroke, TIA
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 8,343 participants (actual)
- Lead sponsor
- Beijing Tiantan HospitalUniversity, hospital or other
- Study start
- 11 Aug 2022 (actual)
- Primary completion
- 13 Jul 2023 (actual)
- Study completion
- 12 Apr 2024 (actual)
- First posted
- 30 Jun 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a multicentre, randomized, double-blind, placebo-controlled, investigator-sponsored study that aims to investigate the efficacy of colchicine in preventing recurrent stroke in the patients with acute minor-to-moderate ischemic stroke or TIA and a hsCRP level of ≥2mg/L.
Detailed description
This is a multicentre, randomized, double-blind, placebo-controlled trial that aims to investigate the efficacy of colchicine in preventing recurrent stroke in the patients with acute minor-to-moderate ischemic stroke or TIA and a hsCRP level of ≥2mg/L. Patients who were eligible to the inclusion criteria and ineligible to the exclusion criteria will be randomly assigned into two groups by a 1:1 ratio. Patients in one arm will receive colchicine initiated with a dose of 1mg per day on days 1 through 3, and continuing with 0.5 mg per day on days 4 through 90, and those in the other arm will receive an equivalent placebo drug. Study visits will be performed on the day of randomization, at discharge, at day 90 and at 1 year. The primary outcome was stroke (ischemic or hemorrhagic) during 90 days of follow-up in an intention-to treat analysis.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Colchicine Group | Experimental | Drug: ColchicinePatients in this arm will receive colchicine for 90 days in addition to standard medical care |
| Placebo Colchicine Group | Placebo comparator | Drug: Placebo colchicinePatients in this arm will receive placebo colchicine for 90 days in addition to standard medical care |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- 40 years or older than 40 years;
- Acute cerebral ischemic event due to: Acute minor-to-moderate ischemic stroke (NIHSS≤5 at the time of randomization) or TIA with moderate-to-high risk of stroke (ABCD2 score ≥ 4 at the time of randomization);
- With a hsCRP level of ≥2mg/L at randomization;
- Can be treated with study drug within 24 hours of symptoms onset*(*Symptom onset is defined by the "last seen normal" principle);
- Informed consent signed.
Key exclusion criteria (21 listed)
- Malformation, tumor, abscess or other major non-ischemic brain disease (e.g., multiple sclerosis) on baseline head CT or MRI.
- Isolated or pure sensory symptoms (e.g., numbness), isolated visual changes, or isolated dizziness/vertigo without evidence of acute infarction on baseline head CT or MRI.
- Iatrogenic causes (angioplasty or surgery) of stroke or TIA.
- Presumed cardiac source of embolus, such as atrial fibrillation or prosthetic cardiac valve).
- A score of ≥ 2 on the modified Rankin scale immediately before the occurrence of the index event.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ColchicineOral colchicine will be initiated with a dose of 1mg per day (one tablet of 0.5mg initially followed by another tablet of 0.5 mg at least four hours later) on days 1 through 3, and continuing with 0.5 mg (one tablet) per day on days 4 through 90. | Drug | Colchicine Group |
| Placebo colchicineOral placebo colchicine will be initiated with a dose of 1mg per day (one tablet of 0.5mg initially followed by another tablet of 0.5 mg at least four hours later) on days 1 through 3, and continuing with 0.5 mg (one tablet) per day on days 4 through 90. | Drug | Placebo Colchicine Group |
Primary outcome
Any new stroke events
Time frame: any time within 90 days
Incidence of any new ischemic or hemorrhagic stroke
5 secondary outcomes
New vascular events
Time frame: any time within 90 days
New ischemic stroke
Time frame: any time within 90 days
Poor functional outcome
Time frame: at 90 days after randomization
New stroke and TIA
Time frame: any time within 90 days
Severity of recurrent stroke and TIA
Time frame: within 90 days after randomization
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jun 2024.
- Derived from this study: PubMed 40496882Li J, Jing J, Meng X, Shi FD, Gu HQ, Jin A, Jiang Y, Li H, Johnston SC, Hankey GJ, Easton JD, Xie X, Jin WN, Chang L, Shi P, Wang L, Zhuang X, Li H, Zang Y, Zhang J, Sun Z, Liu D, Li Y, Yang H, Zhao J, Yu W, Wang A, Pan Y, Lin J, Li S, Niu S, Wang Y, Zhao X, Li Z, Liu L, Zheng H, Wang Y; CHANCE-3 Investigators. Colchicine for preventing stroke in patients with and without intracranial atherosclerotic stenosis: a prespecified analysis of a randomized clinical trial. EClinicalMedicine. 2025 May 19;84:103226. doi: 10.1016/j.eclinm.2025.103226. eCollection 2025 Jun.
- Derived from this study: PubMed 38925803Li J, Meng X, Shi FD, Jing J, Gu HQ, Jin A, Jiang Y, Li H, Johnston SC, Hankey GJ, Easton JD, Chang L, Shi P, Wang L, Zhuang X, Li H, Zang Y, Zhang J, Sun Z, Liu D, Li Y, Yang H, Zhao J, Yu W, Wang A, Pan Y, Lin J, Xie X, Jin WN, Li S, Niu S, Wang Y, Zhao X, Li Z, Liu L, Zheng H, Wang Y; CHANCE-3 Investigators. Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): multicentre, double blind, randomised, placebo controlled trial. BMJ. 2024 Jun 26;385:e079061. doi: 10.1136/bmj-2023-079061.
- Derived from this study: PubMed 37060288Wang Y, Li J, Johnston SC, Hankey GJ, Easton JD, Meng X, Shi FD, Wang Y, Zhao X, Li Z, Liu L, Gu H, Jiang Y, Wang A, Pan Y, Jing J, Niu S, Li H. Colchicine in High-risk Patients with Acute Minor-to-moderate Ischemic Stroke or Transient Ischemic Attack (CHANCE-3): Rationale and design of a multicenter randomized placebo-controlled trial. Int J Stroke. 2023 Aug;18(7):873-878. doi: 10.1177/17474930231172312. Epub 2023 May 11.
- Individual participant dataSharing planned: Yes. Data collected for the study can be made available to other researchers on reasonable request and after signing appropriate data sharing agreements.
Related trials for Ischemic Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
Active, not recruiting
Improving Visual Field Deficits With Noninvasive Brain Stimulation
Visual Field Defect, Peripheral, Stroke
Recruiting
Biomarkers of Paired VNS
Stroke, Ischemic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
244 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Colchicine in people with Ischemic Stroke and TIA, run by Beijing Tiantan Hospital at 244 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Jun 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 244 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Any new stroke events (time frame: any time within 90 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05439356, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jun 2024.